INDIA BUSINESS WORLD - FEBRUARY 1^st - FEBRUARY 15^th - 2008

DABUR PHARMA GETS DCGI NOD FOR NANOXEL

Dabur Pharma has said that it has got approval from the Drug Controller General of India (DCGI) for its anti-cancer drug delivery formulation 'Nanoxel' (nanoparticle paclitaxel) as an indication for three more types of cancer. Nanoxel is a new anti-cancer drug delivery system developed by Dabur Pharma, which allows more targeted treatment and avoid side effects of Chemotherapy. The company informed the stock exchanges that its proprietary Nanoxel has been approved by DGCI for treatment of ovarian Cancer, non-small cell lung cancer and also for AIDS related Kaposis' Sarcoma (abnormal growth of tissues under the skin). "This approval will help a much larger patient population have access to significantly safer and more convenient therapeutic alternative to conventional Paclitaxel," Dabur Pharma CEO Ajay Kumar Vij said in a statement.